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Abstract
Introduction: Papillary thyroid carcinoma and medullary thyroid carcinoma are two different thyroid neoplasia. The
simultaneous occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma as a collison tumor with
metastases from both lesions in the regional lymph nodes is a rare phenomenon.
Case presentation: A 32-year-old Iranian man presented with a fixed anterior neck mass. Ultrasonography
revealed two separate thyroid nodules as well as a suspicious neck mass that appeared to be a metastatic lesion.
The results of thyroid function tests were normal, but the preoperative calcitonin serum value was elevated. Our
patient underwent a total thyroidectomy with neck exploration. Two separate and ill-defined solid lesions grossly
in the right lobe were noticed. Histological and immunohistochemical studies of these lesions suggested the
presence of medullary thyroid carcinoma and papillary thyroid carcinoma. The lymph nodes isolated from a neck
dissection specimen showed metastases from both lesions.
Conclusions: The concomitant occurrence of papillary thyroid carcinoma and medullary thyroid carcinoma and
the exact diagnosis of this uncommon event are important. The treatment strategy should be reconsidered in such
cases, and genetic screening to exclude multiple endocrine neoplasia 2 syndromes should be performed. For
papillary thyroid carcinoma, radioiodine therapy and thyroid-stimulating hormone suppressive therapy are
performed. However, the treatment of medullary thyroid carcinoma is mostly radical surgery with no effective
adjuvant therapy.
Introduction
Papillary thyroid carcinoma (PTC) and medullary thyr-
oid carcinoma (MTC) are two different thyroid neopla-
sia. The former originates from thyroglobulin-producing
follicular cells, whereas the latter arises from calcitonin-
producing cells. MTC is a rare tumor that arises from
neural crest-derived parafollicular C cells. Tumors
showing both features are rare and represent less than
1% of all thyroid malignancies [1] and have different
patterns of clinical presentation and biological behavior.
A review of the literature revealed similar lesions [1-11].
Mutations in the RET gene, rearrangements of the tyro-
sine kinase receptors RET (ret/PTC) and NTRK1, and
point mutation of the BRAF gene have been
documented in PTC tumors [12-15]. However, the exact
pathogenesis of these cases is unknown, but an underly-
ing genetic background has been hypothesized. In this
report, a case of concurrent MTC and PTC has the fea-
tures of a collision tumor.
Case presentation
A 32-year-old Iranian man was admitted for an anterior
neck mass. He had no history of radiation to the head
and neck and no known family history of endocrine dis-
ease. During a physical examination, his nodule was well
demarcated, fixed, and measured about 2.5 cm in its lar-
gest diameter. An ultrasound examination of his neck
showed a 3 cm solid hypoechoic nodule of the right
thyroid lobe and an additional nodule in the lower pole
of the same lobe. A suspicious neck mass that appeared
to be metastatic lymph nodes was noticed. The left thyr-
oid lobe and the isthmus appeared to be normal. Serum
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trophin were within normal ranges, and anti-thyroper-
oxidase/anti-thyroglobulin autoantibodies and anti-
thyroglobulin antibody (anti-Tg Ab) were negative. A
preoperative calcitonin serum value was elevated (40 ng/
L) (chemiluminescence immunometric assay kit with
reference intervals in adults: less than 11.5 ng/L for men
and less than 4.6 ng/L for women). Our patient was
screened for multiple endocrine neoplasia with negative
results. He had normal serum levels of calcium, phos-
phorus, and parathyroid hormone. A chest X-ray and
abdominal ultrasound were unremarkable. Fine needle
aspiration of one nodule revealed papillary clusters that
had atypical nuclei and intranuclear inclusions and that
appeared to be a papillary carcinoma. Our patient
underwent a total thyroidectomy with neck explora-
tion. An enlarged thyroid gland with a prominent right
lobe as well as a mottled lymph node in the right side
were detected during the operation. Surgical specimens
were fixed in 10% buffered formalin, embedded in par-
affin, and stained with hematoxylin and eosin. For
immunohistochemical studies, sections were incubated
with the following primary monoclonal antibodies:
cytokeratin AE1/AE3, chromogranin A, synaptophysin,
thyroglobulin, and calcitonin (Dako Corporation,
Glostrup, Denmark). An EnVision Dual Link system-
H R P( r e a d yt ou s e ;D a k oC o r p o r a t i o n )w a su s e da sa
secondary antibody. Incubation with DAB (3,3’-diami-
nobenzidine tetrahydrochloride) was performed as a
substrate chromogen solution to produce a brown
color. All steps were carried out at room temperature.
Appropriate positive and negative control sections
were processed in parallel. An ill-defined, solid, tan-
colored lesion measuring 3 cm in its greatest diameter
was observed grossly in the right lobe. In the same
lobe, an irregular, whitish lesion measuring 1 cm in its
greatest diameter was also present and was completely
separated from the former lesion. The remaining thyr-
oid tissue was unremarkable. A neck dissection yielded
eight regional lymph nodes.
In light microscopy, two lesions had strikingly differ-
ent morphologies. The largest nodule consisted of a
sheet-like growth of cells with round nuclei and
clumped chromatin with scant amphophilic cytoplasm
( F i g u r e1 ) .M i t o t i ca c t i v i t yw a sl o w ,a n dn oa r e ao f
necrosis or hemorrhage was observed. The stroma con-
tained a homogeneous and pink ground substance.
There was no evidence of C-cell hyperplasia in the rest
of the normal thyroid. Tumor cells were immunoreac-
tive for calcitonin (Figure 2), chromogranin A, and
synaptophysin and were negative for thyroglobulin and
cytokeratin.
The lesion located in the lower pole of the same lobe
showed a papillary growth pattern with nuclear
clearing, nuclear grooving, and occasional pseudoinclu-
sions (Figure 3). These cells were immunoreactive for
thyroglobulin and cytokeratin and were negative for
calcitonin, chromogranin A, and synaptophysin. Four
lymph nodes isolated from the neck dissection speci-
m e ns h o w e dm e t a s t a s i so fM T C ,a n do n eo ft h e m
showed metastatic PTC. The stage of this tumor was
T2N1M0. The result of a genetic analysis of RET
oncogene was negative. For ablation of remnants of
thyroid tissue, our patient received 150 mCi I
131.S i x
months later, a whole-body scan with I
131 was per-
formed in order to find metastatic or active thyroid tis-
sue, but the result was negative. Suppression therapy
with thyroid hormone was performed; during follow-
up, the serum levels of thyroglobulin (normal range is
not more than 60 μg/L), anti-Tg Ab (normal range is
Figure 1 Sheet of polygonal cells with round to elongated
nuclei and clumped chromatin embedded in amorphous
eosinophilic material, adjacent to normal thyroid follicles
(hematoxylin and eosin [H&E] ×100).
Figure 2 Polygonal cells show positive cytoplasmic
immunostaining for calcitonin (immunohistochemistry ×100).
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less than 11.5 ng/L) were routinely checked. The
serum level was undetectable after surgery, and no
increase in these parameters was detected. Our patient
is clinically well 12 months after surgery.
Discussion
The simultaneous occurrence of MTC and PTC in the
same thyroid is a rare phenomenon that can be
observed in two main settings: a mixed tumor showing
dual differentiation [15] or a collision tumor (that is, a
tumor with two separate and different components)
[2-8]. Our case belongs to the latter category since
lesions with features of MTC and PTC were detected in
two different locations and separated by normal thyroid
tissue.
Histopathology and immunohistochemical findings of
the first nodule suggested that it was a small-cell variant
of MTC. Histopathology and immunohistochemical
findings of these nodules were small-cell variants of
MTC and papillary microcarcinoma according to the
current World Health Organization classification of
thyroid tumors.
Our strategy in the treatment of thyroid carcinoma is
similar to guidelines used in Western countries [16]. All
patients were routinely examined by preoperative ultra-
sonography to estimate intrathyroid spread of the
tumor. In patients with clinically involved lateral cervical
lymph nodes detected by ultrasonography or computed
tomography, a modified radical neck dissection was per-
formed. For evaluation of bone and distant metastases,
radioactive iodine whole-body scanning was done.
Before radioactive iodine scanning, any thyroxin treat-
ments were discontinued for four weeks and patients
were placed under strict restriction of iodine-containing
food for two weeks. Postoperative radioiodine therapy
and thyroid-stimulating hormone suppressive therapy
were performed. During follow-up, the serum levels of
thyroglobulin, anti-Tg Ab, and calcitonin were routinely
checked.
The coexistence of PTC and MTC has been reported
in the literature [1-11]. These tumors occurred together
more frequently in women, presented with a palpable
neck mass, and were treated with surgery. Metastatic
foci of either PTC or MTC were detected in few
patients [4,6,7]. These lymph node metastases show
pure tumor cell populations of one or two components
or an admixture of both components within the same
lymph node [9,17]. Distant metastases were described
mostly in the mediastinum, lung, liver, and bone [18].
Fugazzola and colleagues [3] reported the familial clus-
tering for these types of tumors, but the exact pathogen-
esis of these thyroid malignancies is completely
unknown. Genetic analysis of RET oncogene in reported
cases had conflicting results. Brauckhoff and colleagues
[19] and Papi and colleagues [20] reported that germline
point mutation of the RET gene had a potential role in
the development of both MTC and PTC. However,
according to Cerrato and colleagues [21], half of spora-
dic MTCs do not carry RET mutations and other genes,
such as RB (retinoblastoma) and TP53 tumor suppressor
pathways, may be involved in MTC formation. Rossi and
colleagues [1] reported that both the RET and BRAF
genes had a role in the genesis of the medullary-papil-
lary collision tumors. The RET proto-oncogene plays a
key role in the development of MTC. Vantyghem and
colleagues [10] reported 11 cases of familial MTC-PTC
according to clinical, histologic, or family features (or a
combination of these features), but no RET defects were
present. The authors suggested that another gene or
uncommon abnormality of the RET gene was responsi-
ble for tumorgenesis. A recent animal study by Miller
and colleagues [22,23] suggested that the PI3K or Ras
signaling cascade alone was unable to transform thyroid
follicular cells but that simultaneous activation had inva-
sive and metastatic potential. Overall, the molecular evi-
dence suggested that the two components of these
heterogeneous groups of tumors were not derived from
a common stem cell [23,24]. The origin of each carci-
noma is embryologically different because the C cells
stem from an ultimobranchial body that derived from
the fourth pharyngeal pouch, whereas the thyroglobulin
and thyroid hormone-producing cells come from the
follicular epithelial cells derived from a median endoder-
mal anlage from the tongue.
Conclusions
In this case, the simultaneous occurrence of MTC and
PTC presented as two distinct and well-defined tumor
Figure 3 Papillary structure lined by cuboidal to columnar cells
with eosinophilic cytoplasm and occasional nuclear inclusions
(hematoxylin and eosin [H&E] ×100).
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gical variants that resemble follicular, papillary, and
undifferentiated carcinoma. The immunohistochemical
studies for calcitonin along with thyroglobulin negativity
usually confirm the C-cell origin of tumor cells. Overall,
mixed MTC-PTC is a rare clinical entity and should be
considered in the differential diagnosis of thyroid
tumors, particularly in patients with a family history of
thyroid malignancy.
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